Defective DNA Damage Response is a Targetable Therapeutic Vulnerability in ESR1 Mutant Breast Cancer.

已完结 20 由达姆发布于 2026/1/15 15:47:31

DOI:10.1158/0008-5472.can-24-3891
作者：Sarah K Herzog,Jessica H Stevens,Guowei Gu,Sandra L Grimm,Kloma Cardoza,Autumn G M Hawkins,Hangqing Lin,Daniela Ramos,Amanda R Beyer,David G Edwards,Derek Dustin,Harry J Yang,Nicole Liang,Ashfia F Kha
文献类型：期刊论文
补充材料：只需要正文

American Association for Cancer Research (AACR)

Abstract：ESR1 mutations are the leading cause of endocrine therapy resistance and progression in ER-positive metastatic breast cancer. ESR1 mutations are detected in ~50% of metastatic breast cancer

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:WileyScreening Natural Cholesterol Analogs to Assemble Self-Adjuvant Lipid Nanoparticles for Antigens Tagging Guided Therapeutic Tumor Vaccine